Molecular insights into the development of T cell-based immunotherapy for prostate cancer

Baijun Dong, Laurie J. Minze, Wei Xue, Wenhao Chen

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Using a patient's own immune system to fight cancer is a highly active area of cancer research. Four years ago, sipuleucel-T became the first approved cancer vaccine, which was developed to enhance T-cell immunity against metastatic castration-resistant prostate cancer. Other prostate cancer vaccines, including a viral-based vaccine PROSTVAC-VF and a cellular vaccine GVAX, are in development. Moreover, several clinical trials are investigating the role of immune checkpoint blockade in the treatment of prostate cancer. Ipilimumab and nivolumab are potent T cell checkpoint inhibitors that reverse immunologic tolerance in multiple types of cancers. Here we discuss the mechanisms underlying antitumor T cell responses as well as the development of immunotherapies for prostate cancer.

Original languageEnglish (US)
Pages (from-to)1547-1557
Number of pages11
JournalExpert Review of Clinical Immunology
Issue number11
StatePublished - Nov 1 2014


  • T cells
  • cancer vaccine
  • immune checkpoint
  • immunotherapy
  • prostate cancer
  • sipuleucel-T

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Molecular insights into the development of T cell-based immunotherapy for prostate cancer'. Together they form a unique fingerprint.

Cite this